Search Weight Loss Topics:

Page 402«..1020..401402403404..410420..»

Home » Page 402

The latest independent research document on Global Human Growth Hormone (HGH) examine investment inMarket. It describes how companies deploying these technologies across various industry verticals aim to explore its potential to become a major business disrupter. The Human Growth Hormone (HGH) study eludes very useful reviews & strategic assessment including the generic market trends, emerging technologies, industry drivers, challenges, regulatory policies that propel the market growth, along with major players profile and strategies. This version of Human Growth Hormone (HGH) market report advocates analysis of Sandoz International, Ipsen, GeneScience Pharmaceuticals, Anhui Anke Biotechnology (Group), BioPartners, Ferring Pharmaceuticals, F. Hoffmann-La Roche, Novo Nordisk, Merck Serono, LG Life Sciences, Teva Pharmaceutical Industries, Eli Lilly & Pfizer.

Get Free Sample Pages of Global Human Growth Hormone (HGH) Market Study Now @:https://www.htfmarketreport.com/sample-report/3399826-2020-2025-global-human-growth-hormone

As Human Growth Hormone (HGH) research and application [Growth Hormone Deficiency, Turner Syndrome, Chronic Renal Insufficiency, Prader Willi Syndrome, Small for Gestational Age & SHOX Deficiency] continues to expand in scope, the market will see deeper integration and application of more technologies in the future. This commercialization of market is playing a positive role in accelerating Human Growth Hormone (HGH) business digitalization, improving industry chain structures and enhancing information use efficiency. The findings mainly focus on category or product type: , Powder & Solvent etc, which underpins many recent advances in the other Human Growth Hormone (HGH) technologies.

In order to provide a more informed view, Human Growth Hormone (HGH) research offers a snapshot of the current state of the rapidly changing industry, looking through the lenses of both end users and service provides/players ofto come up with a more robust view.

Market Scope

Based on the type of product, themarket segmented into :, Powder & Solvent

Based on the End use application, themarket segmented into :Growth Hormone Deficiency, Turner Syndrome, Chronic Renal Insufficiency, Prader Willi Syndrome, Small for Gestational Age & SHOX Deficiency

Buy this research report @https://www.htfmarketreport.com/buy-now?format=1&report=3399826

Regional Landscape

Geographically, the Human Growth Hormone (HGH) market size by revenue is broken down by 18+ countries fromNorth America, LATAM, the Middle East, Asia Pacific, Africa, and Europebased on various characteristics such as geographic footprints and business operation locations of players.

Analysts at HTF MI sheds light on Human Growth Hormone (HGH) market data by Country

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, South Korea, Thailand, India, Indonesia, Australia and Others)Europe (Germany, Russia, the UK, Italy, France, Spain, Belgium, Netherlands, Switzerland, Nordic Nations, Rest of Europe.)North America (the United States, Mexico, and Canada)South America (Brazil, Argentina, Chile, Rest of South America)Middle East and Africa (GCC Countries, Turkey, Israel, South Africa, Egypt and Rest of MEA)

The Human Growth Hormone (HGH) study cites various market development activities and business strategies such as new product/services development, Joint Ventures, partnerships, mergers and acquisitions, etc that Industry players such as Sandoz International, Ipsen, GeneScience Pharmaceuticals, Anhui Anke Biotechnology (Group), BioPartners, Ferring Pharmaceuticals, F. Hoffmann-La Roche, Novo Nordisk, Merck Serono, LG Life Sciences, Teva Pharmaceutical Industries, Eli Lilly & Pfizer are utilizing to overcome macro-economic scenarios. The Human Growth Hormone (HGH) Market company profiles include Business Overview, Product / Service Offerings, SWOT Analysis, Segment & Total Revenue, Gross Margin and % Market Share.

Not Matching with Business Objective? Enquire for Customize Report @https://www.htfmarketreport.com/enquiry-before-buy/3399826-2020-2025-global-human-growth-hormone

Extracts from Global Human Growth Hormone (HGH) Market Study

1. Market Snapshot2. Global Human Growth Hormone (HGH) Market Factor Analysis Value Chain Analysis Growth Drivers, Trends and Challenges Porters 5- Forces Analysis PESTEL Analysis3.Human Growth Hormone (HGH) Market by Type (2016-2026) [, Powder & Solvent]4. Market by Applications/ End Users (2016-2026) [Growth Hormone Deficiency, Turner Syndrome, Chronic Renal Insufficiency, Prader Willi Syndrome, Small for Gestational Age & SHOX Deficiency]5.Human Growth Hormone (HGH) Market: Country Landscape6. Market Size Breakdown for Each Country7. Competitive Landscape Market Share Analysis by Players Company Profiles

.. Continued

Data Sources & Methodology

The primary sources involve the industry experts from the Global Human Growth Hormone (HGH) Market including the management organizations, processing organizations, service providers of the industrial value chain. In the extensive research process undertaken for this study, the primary sources considered such as Postal Surveys, telephone, Online & Face-to-Face Survey to obtain and verify both qualitative and quantitative aspects. When it comes to secondary sources Companys Annual reports, press Releases, Websites, Investor Presentation, Conference Call transcripts, Webinar, Journals, Regulators, National Customs and Industry Associations were used.

Read Detailed Index of full Research Study at @https://www.htfmarketreport.com/reports/3399826-2020-2025-global-human-growth-hormone

Thanks for reading Human Growth Hormone (HGH) Industry research publication; you can opt for regional report version like Western Europe, USA, China, Southeast Asia, LATAM, APAC etc. Also, we can serve you with customize research services as HTF MI holds a database repository that includes Public organizations and Millions of Privately held companies with expertise across various Industry domains.

About Author:HTF Market Intelligence consulting is uniquely positioned empower and inspire with research and consulting services to empower businesses with growth strategies, by offering services with extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist in decision making.

Contact US:Craig Francis (PR & Marketing Manager)HTF Market Intelligence Consulting Private LimitedUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218sales@htfmarketreport.com

Connect with us atLinkedIn|Facebook|Twitter

See the rest here:
Human Growth Hormone (HGH) Market SWOT Analysis by Size, Status and Forecast to 2021-2027 The Manomet Current - The Manomet Current

Read More..

EL CAJON

Mark Klaus, president and CEO of the East County-based Home of Guiding Hands for the past 11 years, has been tapped to lead the San Diego Regional Center, one of the countys largest nonprofits.

Klaus is credited with helping Home of Guiding Hands, which serves people with developmental challenges, grow from 400 to 4,000 clients.

Starting Nov. 1, Klaus will take over as executive director of the San Diego Regional Center, which serves about 34,000 clients in San Diego and Imperial counties. Klaus was named the head of the SDRC on Tuesday by a unanimous vote of the centers governing board.

The SDRC is one of 21 similar centers in California, all of which work with community partners like Home of Guiding Hands to serve more than 380,000 individuals with developmental disabilities. The Regional Center works with families of individuals with developmental challenges to help them achieve their goals.

Klaus will follow Carlos Flores, 66, who started with the center in 1999, became executive director in 2007, and was set to retire early in 2020, right before the COVID-19 pandemic hit. He stayed to see the 650-employee center through the health emergency.

San Diego Regional Center Board Chair Shirley Nakawatase said Klaus is the perfect fit. She cited Klaus and Flores close working relationship as key to a seamless transition. The two leaders have taken many trips to state and national legislatures, lobbying for developmentally challenged persons, their caretakers and families.

Mark Klaus will be the new Executive Director at the San Diego Regional Center

(Nadia Borowski Scott/ Alchemy MediaWorks)

Among other accomplishments, under Klauss leadership, HGH developed a program that concentrates on helping families with newborns through age 3. He helped 60-year-old HGH advance more community-based services and navigate 30 residential homes for adults with developmental disabilities.

Klaus will earn about $360,000 in his new role at the Regional Center. The groups operating budget is about $70 million of its overall $600 million budget. The group operates its programs and eight offices seven in San Diego County, one in the city of Imperial through grants and government assistance, mostly from the state Department of Developmental Services.

Over the last 510 days, working even closer with Carlos and his staff, I saw firsthand their values, their culture, their desires and I saw they are really aligned with Home of Guiding Hands and what I believe in, said Klaus, 58. I am grateful to have the opportunity to have an even larger impact on the people we serve.

Klaus said that while a high school student in Illinois, he volunteered with a company that worked with individuals with disabilities, not thinking at the time that it would become his future avocation.

After earning a bachelors degree in economics from the University of Illinois, he started working in the field and worked his way up to President and Chief Executive Officer of Charleston Transitional Facility in Champaign, Ill. He later spent 10 years heading the nonprofit CTF Illinois, which provides programs and services for those with developmental disabilities and mental illness.

Visit link:
Home of Guiding Hands leader takes new job at San Diego Regional Center - The San Diego Union-Tribune

Read More..

The Infrared Line Scanners market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, the impact of domestic and global market players like HGH INFRARED SYSTEMES, NDC Technologies, INTERMEC, Optris, Fluke, GESOTEC, etc., value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The Key Areas That Have Been Focused in the Report:

Get Exclusive Sample of Report on Infrared Line Scanners market @ https://www.affluencemarketreports.com/industry-analysis/request-sample/1550630/

Infrared Line Scanners Market Segmentation:

Infrared Line Scanners market is split by Type and by Application. For the period 2016-2026, the growth among segments provides accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Infrared Line Scanners Market Report based on Product Type:

Infrared Line Scanners Market Report based on Applications:

The key market players for global Infrared Line Scanners market are listed below:

Get Extra Discount on Infrared Line Scanners Market Report, If your Company is Listed in Above Key Players List @ https://www.affluencemarketreports.com/industry-analysis/request-discount/1550630/

Promising Regions & Countries Mentioned in Infrared Line Scanners Market Report:

TABLE OF CONTENTS INCLUDE

Consumption Forecast, Market Opportunities & Challenges, Risks and Influences Factors Analysis, Market Size by Application, Market Size by Manufacturers, Market Size by Type, Infrared Line Scanners Consumption by Regions, Infrared Line Scanners Production by Regions, Production Forecasts, Value Chain and Sales Channels Analysis, Key Findings in the Global Infrared Line Scanners Study, Manufacturers Profiles

Report Customization: Clients can request for customization of report as per their need for additional data.

CONTACT FOR ADDITIONAL CUSTOMIZATION @ https://www.affluencemarketreports.com/industry-analysis/request-inquiry/1550630/

Impact of COVID-19 on Infrared Line Scanners Market

The report also contains the effect of the ongoing worldwide pandemic, i.e., COVID-19, on the Infrared Line Scanners Market and what the future holds for it. It offers an analysis of the impacts of the epidemic on the international Market. The epidemic has immediately interrupted the requirement and supply series. The Infrared Line Scanners Market report also assesses the economic effect on firms and monetary markets. Futuristic Reports has accumulated advice from several delegates of this business and has engaged from the secondary and primary research to extend the customers with strategies and data to combat industry struggles throughout and after the COVID-19 pandemic.

For More Details on Impact of COVID-19 on Infrared Line Scanners Market https://www.affluencemarketreports.com/industry-analysis/covid19-request/1550630/

Frequently Asked Questions

About Affluence:

Affluence Market Reports is the next generation of all your research needs with a strong grapple on the worldwide market for industries, organizations, and governments. Our aim is to deliver exemplary reports that meet the definite needs of clients, which offers an adequate business technique, planning, and competitive landscape for new and existing industries that will develop your business needs.

We provide a premium in-depth statistical approach, a 360-degree market view that includes detailed segmentation, key trends, strategic recommendations, growth figures, Cost Analysis, new progress, evolving technologies, and forecasts by authentic agencies.

For more Details Contact Us:

Affluence Market Reports

Contact Person: Mr. Rohit

Phone Number:

U.S: +1-(424) 256-1722

U.K.: +44 1158 88 1333

Email: [emailprotected]

Website: http://www.affluencemarketreports.com

Follow this link:
Overview Infrared Line Scanners Market 2021-2026 Business Analysis by Top Companies like HGH INFRARED SYSTEMES, NDC Technologies, INTERMEC, Optris,...

Read More..

Ads for the latest drugs to treat Type 2 diabetes sometimes include an unusual warning: They might cause weight loss. That side effect is one that many people especially those with Type 2 diabetes, which is associated with obesity may desperately want.

Now some of the same drugs are being reformulated and renamed by manufacturers as a new obesity treatment. Last month, the Food and Drug Administration approved one of the first: Novo Nordisks Wegovy, a higher-dose version of the companys injectable diabetes drug, Ozempic.

Wegovys monthly wholesale price set at $1,349 is about 58% more than Ozempics already high monthly cost, although, the company points out, Wegovys injector pens contain more than twice as much of the active ingredient. That it also probably needs to be taken long term adds to the dilemma facing employers and insurers, who must now dive into a cost-benefit analysis.

Its too early to know yet how many employers will cover Wegovy, although about 40% currently offer a similarly priced, but less effective, weight-loss injectable drug also made by Novo Nordisk. Wegovys effectiveness may also put pressure on the Medicare program, which bars coverage for obesity medications or others used for anorexia, weight loss or weight gain, although it does pay for bariatric surgery.

Clinical trials showed using Wegovy led to significant weight loss for many patients.

People who go on this medication lose more weight than with any drug weve seen, ever, said Dr. Fatima Cody Stanford, an obesity medicine specialist at Massachusetts General Hospital and Harvard Medical School who was not involved with any of the clinical trials.

Studies so far show that patients may need to take it indefinitely to maintain weight loss, translating to a tab that could top $323,000 over 20 years at the current price.

The arrival of this new class of weight loss drugs one from Lilly may soon follow has created a thicket of issues for those who will pay for them. But its an attractive market for drugmakers: Type 2 diabetes affects about 10% of Americans, but obesity affects 42% of adults.

Maryland resident Phylander Pannell said she lost 65 pounds in a clinical trial of Wegovy. That study gave the drug to all participants for the first 20 weeks, then randomly assigned patients to receive either the drug or a placebo for the next 48 weeks to determine what happened when the medication was stopped. Only after the trial ended did Pannell find out she was in the treatment group the entire time.

Her weight fell slowly at first, then ramped up, eventually bringing her 190-pound frame down to about 125. Pains in her joints eased; she felt better all around.

I definitely feel the drug was it for me, said Pannell, 49, who also followed the trials guidance on diet and exercise. The study found that both groups lost weight in the initial 20 weeks, but those who continued to get the drug lost an additional average of 7.9% of their body weight. Those who got a placebo gained back nearly 7%.

After the trial ended, and the COVID-19 pandemic hit, Pannell regained some weight, and is now at 155. She is eager to get back on the medication and hopes her job-based insurance will cover it.

Many employers do cover obesity drugs. For example, about 40% of private employer plans include Novo Nordisks once-daily injection called Saxenda on their health plans, said Michael Bachner, Novo Nordisks director of media relations.

A cycling team holds a meet and green in London on Wednesday. The team, made up of riders who have diabetes, is sponsored by Novo Nordisk, whose diabetes drug is being repurposed for weight loss.

(Jack Thomas / Getty Images)

He said the $1,349-a-month wholesale acquisition price of Wegovy was determined by making it equivalent to Saxenda, which is less effective.

Still, that is more than the $851 monthly wholesale price of Ozempic. But, he points out, the recommended dosage of Wegovy is more than twice that of Ozempic. Four milligrams come in the Ozempic injector pens for the month, while Wegovy has 9.6.

Theres more drug in the pen, Bachner said. That drives the price up.

He added: This is not a 20-year-old drug that we now have a new indication for and are pricing it higher. Its a whole different clinical program, which required new trials.

As employers and their health plans consider whether to pay for Wegovy and other weight management drugs, the decision is complicated by many unknowables concerning their long-term use and whether competition might eventually lower the price.

The metric we try to use is value, said James Gelfand, senior vice president for health policy at the ERISA Industry Committee, which represents large, self-insured employers. If we pay for this drug, how much is this going to cost, and how much value will it provide to the beneficiaries?

Private insurers will have to consider a cost-benefit analysis of adding Wegovy to their list of covered treatments, either broadly or with limits. Obesity was first recognized as a disease by the American Medical Assn., easing the path for insurance coverage, in 2013.

Employers are going to have a bit of a challenge deciding whether to add the benefit to insurance offerings, said Steve Pearson, founder and president of the Institute for Clinical and Economic Review, which provides cost-benefit analyses of medical treatments but has not yet looked at Wegovy.

Weight loss treatments have had a lackluster past, producing only modest results. Many employers and insurers probably remember Fen-Phen, a combination of fenfluramine and dexfenfluramine that was pulled from the market in the late 1990s for causing heart valve problems.

That Wegovy, and possibly others that follow it, appear more effective but are also pricier than the small number of previous weight loss medications will add more fuel to that debate.

Past treatments were shown to prompt weight loss in the range of 5% to 10% of body weight. But many had relatively serious or unpleasant side effects.

Wegovy, however, helped patients lose an average of 15% of their body weight over 68 weeks in the main clinical trial that led to its approval.

A comparison group whose members received placebo injections lost an average of 2.5% over the same period. On the high end, nearly a third of patients in the treatment group lost 20% or more. Both groups had counseling on diet and exercise.

Side effects, generally considered mild, included nausea, diarrhea, vomiting and constipation. A few patients developed pancreatitis, a serious inflammation of the pancreas. Like the diabetes medication, the drug carries a warning about a potential risk of a type of thyroid cancer.

Weight loss in those taking Wegovy puts the drug close to the 20% to 25% losses seen with bariatric surgery, said Stanford at Mass General, and well above the 3% to 4% seen with diet and other lifestyle changes alone.

Participants also saw reductions in their waistlines and improvements in their blood pressure as well as their blood sugar levels, which may mean they wont develop diabetes, said Dr. Sean Wharton, an internal medicine specialist and adjunct professor at York University in Toronto who was among the coauthors of the report outlining the results of the first clinical trial of Wegovy.

Since weight loss is known to reduce the risk of heart attack, high blood pressure and diabetes, might the new drug type be worth it?

Covering such treatment would be a sea change for Medicare.

Pharmaceutical companies, patient advocates and some medical professionals are backing proposed federal legislation to allow coverage. But the legislation, the Treat and Reduce Obesity Act, has not made progress despite being reintroduced every year since 2012, and sponsors are now asking federal officials instead to rewrite existing rules.

Earlier estimates some commissioned by Novo Nordisk of the potential cost of adding an obesity drug benefit to Medicare showed an overall reduction in spending when better health from the resulting weight loss was factored in. Still, those estimates considered much less expensive drugs, including a range of generic and branded drugs costing $7 a month to more than $300, a small fraction of Wegovys cost.

Appleby writes for Kaiser Health News, an editorially independent publication of the Kaiser Family Foundation.

Read the original post:
Wegovy, the newest weight loss drug, comes with a high cost - Los Angeles Times

Read More..

Health Canada

By Randi-Marie Adams

Aug 3, 2021 | 3:46 PM

PRINCE GEORGE Its easy to get caught up in the million and one fad diets that are out there right now, one super popular one at the moment is Keto. Ketogenic is a term for a low-carb diet. The idea is for you to get more calories from protein and fat and less from carbohydrates.

When it comes to fad diet, I mean there are so many out there and they are always changing, even as a dietitian its hard to keep on top of whats going on in the fad diet world, says Angela Hubbard, Registered Dietitian, Certified Diabetes Educator But, really the research is showing that pretty much any diet that you follow can get you results. Now the problem here is consistency and so when we are talking about something like keto, for example, its really hard. I dont care what anyone tells you. You know I have worked with people, who say hey, half my office is getting results with keto and that may be true, but is it going to be long-term.

Also, there are many people who use diet or food tracking apps. Angela says those are number-based and not flexible for the individual. Finally, THROW YOUR SCALE AWAY. Dont let it define your weight loss journey. Angela says, there are other things to focus on when trying to lose weight.

So, these tracking apps, there are some really great ones, but we have to pay attention to the fact that these apps are very numbers-based, and that sets us up for just paying attention to just the number on the scale, which doesnt mean health.

Visit link:
TYH Eating & Weight loss - CKPGToday.ca

Read More..

SAN CLEMENTE, CA / ACCESSWIRE / August 3, 2021 / ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss solutions company, today announced CEO Bart Bandy's featured interview on the Big Biz Show, a local-San Diego business talk show.

"We are grateful for the opportunity to talk with the hosts of the Big Biz Show, a program focused on giving a platform to businesses on a serial growth path. Over the past few months, we have achieved some significant milestones that optimally position the Company for continued success, and we were pleased to share our progress and current focus with Sully and Russ," commented Bart Bandy, President and Chief Executive Officer at ReShape Lifesciences.

The Big Biz Show interview can be viewed via the following link:

ABOUT RESHAPE LIFESCIENCES INC.

ReShape Lifesciences is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band Program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. reshapecare is a virtual weight-management program that supports lifestyle changes for all weight-loss patients led by board certified health coaches to help them keep the weight off over time. The recently launched ReShape Marketplace is an online collection of quality wellness products curated for all consumers to help them achieve their health goals.

Story continues

Forward-Looking Safe Harbor Statement:

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this press release include statements about our commitment to establishing ReShape Lifesciences as the predominant access source for best-in-class weight loss pathways, products and services. These forward-looking statements are based on the current expectations of our management and involve known and unknown risks and uncertainties that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in our annual report on Form 10-K filed March 11, 2021. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.

CONTACTS:

ReShape Lifesciences Investor Contact: Thomas StankovichChief Financial Officer949-276-6042ir@ReShapeLifesci.com

Investor Contacts:James Salierno/Daniel Kontoh-BoatengVice PresidentThe Ruth Group646-536-7028/7019jsalierno@theruthgroup.comdboateng@theruthgroup.com

SOURCE: ReShape Lifesciences Inc.

View source version on accesswire.com: https://www.accesswire.com/658063/ReShape-LifesciencesTM-CEO-Bart-Bandy-Featured-on-the-Big-Biz-Show

See the rest here:
ReShape Lifesciences(TM) CEO Bart Bandy Featured on the Big Biz Show - Yahoo Finance

Read More..

Pardee Bariatrics and Weight Loss meets all criteria as a MBSAQIP-Accredited Center, according to national quality standards established to deliver safe, high quality metabolic and bariatric patient care

Pardee UNC Health Care Bariatric and Weight Loss has received Comprehensive Center of Excellence accreditation from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program(MBSAQIP). The national accreditation is reserved for bariatric care programs that meet the highest standards for patient safety and quality of care.

The MBSAQIP is a joint Quality Program of the American College of Surgeons (ACS) and the American Society for Metabolic and Bariatric Surgery (ASMBS). As an MBSAQIP accredited center, Pardee ensures bariatric surgery patients receive a multidisciplinary program, which improves patient outcomes and long-term success. Additionally, Pardee offers preoperative and postoperative care designed specifically for their severely obese patients.

Pardee is committed to providing the high-quality care for our patients, said Chris Edwards, M.D., FACS, a board-certified and fellowship-trained bariatric surgeon, and medical director of Pardee Bariatrics and Weight Loss. Certification by MBSAQIP is one of the ways that we ensure we maintain the highest standards and achieve the best possible results for individuals suffering from obesity.

Pardees commitment to quality care begins with expertly trained staff and the leadership of an experienced bariatric surgeon. The program is tasked with continuous review of surgical data to continue improving the structure and outcomes expertise necessary to provide safe, efficacious, and high-quality care to all metabolic and bariatric patients.

To earn MBSAQIP Accreditation, Pardee met essential criteria for staffing, training, facility infrastructure and patient care pathways, ensuring its ability to support patients with obesity. The center also participates in a national data registry that yields semiannual reports on the quality of its surgical outcomes and identifying opportunities for quality improvement. The MBSAQIP Standards, Optimal Resources for Metabolic and Bariatric Surgery, are published by the ACS and the ASMBS.

After applying for MBSAQIP Accreditation, centers undergo an extensive site visit by an experienced bariatric surgeon who reviews the center's structure, processes, and clinical outcomes data. Centers that earn accreditation are awarded a specific designation level, depending on how many patients it serves annually, critical care capabilities, the types of procedures provided, and whether it provides care to patients under the age of 18.

The Centers for Disease Control and Prevention (CDC) estimates about 93 million adults in the United States are affected by obesity and that number continues to increase. The disease of obesity increases the risks of morbidity and mortality because of the diseases and conditions that are commonly associated with it, such as type II diabetes, hypertension, cardiovascular disease, and cancer, among other health risks. Metabolic and bariatric surgery has proven to be effective in the reduction of comorbid conditions related to obesity.* Working together, the ACS and the ASMBS have developed accreditation standards for metabolic and bariatric surgery to assist patients with obesity in identifying centers that provide optimal patient care.

________________________

*Buchwald H, Avidor Y, Braunwald E, et al. Bariatric Surgery: A Systematic Review and Meta-analysis. JAMA. 2004;292(14):1724-1737. DOI:10.1001/jama.292.14.1724.

About the American College of Surgeons

The American College of Surgeons (ACS) is a scientific and educational organization of surgeons that was founded in 1913 to raise the standards of surgical education and practice and to improve the quality of care for surgical patients. Its achievements have placed it at the forefront of American surgery and have made the College an important advocate for all surgical patients. The College has more than 82,000 members and is the largest organization of surgeons in the world.

About the American Society for Metabolic and Bariatric Surgery

The American Society for Metabolic and Bariatric Surgery (ASMBS) is the largest organization for metabolic and bariatric surgeons in the world, with more than 4,200 members. It is a not-for-profit organization that works to advance the science of metabolic and bariatric surgery. The ASMBS is committed to educating medical professionals and the lay public about metabolic and bariatric surgery, including the associated risks and benefits, as a treatment option for obesity.

Read more here:
Pardee UNC Health Care accredited as Comprehensive Center of Excellence by the MBASQQIP - Pardee Hospital

Read More..

BALTIMORE--(BUSINESS WIRE)--Glyscend Inc presented data during the American Diabetes Association 80th Scientific Sessions virtual meeting, June 25-29, 2021, from a study of its proprietary oral polymer duodenal exclusion therapy. The positive data were presented ahead of Glyscends phase I clinical trials, which have commenced recruiting healthy subjects in South Australia.

Glyscend is developing a new class of oral gut-restricted therapies targeting mechanisms underlying bariatric surgery and validated by endoscopic approaches, which have shown to be beneficial in type 2 diabetes (T2D). Glyscends therapy is intended to temporarily augment the natural mucus barrier lining in specific portions of the GI tract and affect hormonal signaling via the gut-liver-brain axis. The novel synthetic polymers are inert, non-absorbed, and naturally eliminated through the GI tract within 24 hours.

The study evaluated the metabolic effects of its therapeutic (GLY-POL) in a non-obese T2D Goto-Kakizaki (GK) rat model, compared to control. Eight weeks of administering GLY-POL once daily resulted in a robust reduction in fasting plasma glucose and post-prandial glucose (PPG) as well as insulin resistance. Oral glucose tolerance testing performed after chronic GLY-POL therapy resulted in a profound reduction of PPG (incremental area under curve (iAUC) = 60 70%) compared to control, with the reduction amplified with duration of therapy. Similar reduction in PPG iAUC was evident during mixed meal tolerance testing (iAUC > 55%), suggesting that oral, polymer-based duodenal exclusion therapy is a viable method of improving glucose homeostasis. The GLY-POL therapy, when given once a day, resulted in a 6% weight loss compared to control (p<0.005), without a difference in food intake between the groups.

The technology we have developed was inspired by the remarkable efficacy of gastric bypass surgery in correcting the metabolic alterations associated with type 2 diabetes. However, these procedures will likely never scale to meet the burgeoning T2D epidemic, due to surgical risks, invasiveness, access, and high cost, stated Ashish Nimgaonkar, MD, President and CEO of Glyscend, and a gastroenterologist at The Johns Hopkins Hospital.

Our goal is to develop an oral medication that works locally in the gastrointestinal tract to provide the benefits of gastric bypass surgery while greatly reducing the costs, as well as the potential risks and complications, according to Dr. Nimgaonkar.

Thomas Jozefiak, PhD, Co-Founder and Chief Scientific Officer of Glyscend noted that While the data confirm a key role for chronic duodenal exclusion in restoring glucose homeostasis, ongoing research and development continue to provide further understanding of the impact that polymer science can play in shaping future therapies in the metabolic disease space.

Glyscend is set to initiate the first-in-human trials to test the safety of its lead compound (GLY-200). The recruitment of healthy participants as part of the phase I study has initiated in Adelaide, South Australia.

Additional data will be presented as an oral presentation at the European Association for the Study of Diabetes (EASD) annual meeting in September, 2021.

In June 2020, Glyscend Therapeutics received US$20.5M Series A investment in a funding round led by Sant Ventures and Australias Brandon Capital through its Medical Research Commercialization Fund (MRCF) with support from Breakout Labs, a fund in the Thiel Foundation.

About Glyscend, Inc.

Glyscend Therapeutics is a venture-backed biopharmaceutical company developing novel orally-delivered compounds that work on targets inside the GI tract to treat a variety of metabolic disorders, including T2D. Glyscends polymer technology platform evolved from research at Johns Hopkins University, where scientists were evaluating the mechanisms that result in significantly improved glucose and metabolic regulation following certain types of bariatric surgery. Glyscends technology was invented through research that originated at Johns Hopkins University and was licensed from the University. The company is headquartered in Baltimore, MD, and performs materials science R&D at JLABS @ M2D2 in Lowell, MA. For more information, please visit http://www.glyscend.com.

About Glyscends Polymer-based Therapy

Glyscends patient-friendly, orally administered polymer therapy is intended to work locally in the GI tract by temporarily augmenting the natural mucus barrier lining in specific portions of the intestine. This barrier would alter food uptake in those portions of intestine to induce dramatic changes in hormonal signaling via the gut-liver-brain axis. Glyscend aims to replicate the beneficial effects of bariatric surgery via the duodenal exclusion mechanism, without the need for surgery. The duodenal exclusion mechanism has been well validated via other invasive endoscopic approaches. Bariatric surgery has been shown to have immediate and profound effects on improving blood glucose while reducing body weight and reducing long-term micro- and macro-vascular complications related to T2D. Glyscends technology could enable, not just the treatment but potentially a reversal of T2D. Glyscends novel synthetic polymers are inert, non-absorbed, and naturally eliminated through the GI tract within 24 hours. Polymer-based therapies are a proven unique class of therapeutics with more than three decades of clinical experience in a wide range of applications. Ongoing research and development continue to provide further understanding of the impact that polymer science can play in shaping future therapies in the metabolic disease space.

Continued here:
Glyscend Therapeutics Announces Preclinical Data at ADA 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Therapy - Business...

Read More..

In our health-conscious and supplement-laden world, its not uncommon for people to swallow a handful of different capsules with their breakfast. Some of the most commonly taken supplements have been shown to have some real health benefits.

But a new study has called one of the most popular dietary supplements, and one many folks have been taking for years to lower cholesterol and boost heart health, into question. Omega-3s, it turns out, might not be all theyre cracked up to be for cardiovascular health at least not ones that are formulated in a certain way.

Omega-3s have been a supplement mainstay because of the key role these fatty acids are known to play in our heart and brain health. Since your body doesnt produce these nutrients on its own, the only way to obtain them is through outside sources.

Seafood particularly oily fish, such as salmon, mackerel, and tuna is a rich natural source of omega-3 fatty acids. A wealth of evidence suggests that individuals who eat seafood at least twice a week have a lower risk of dying of heart disease.

Many people take supplements that contain omega-3 fatty acids in the belief that these will also help protect them against cardiovascular disease. And some research has found that omega-3 fatty acid supplements significantly reduced the odds of heart attack.

But a research team at the Intermountain Heart Institute in Utah says that if taken a certain way, omega-3s dont do much for your heart, and in some cases may even be harmful.

RELATED: Everything You Need to Know About Omega-3s

There are two types of omega-3 fatty acids commonly found in supplements: DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid). EPA and DHA are found naturally in fatty fish like salmon and mackerel and are widely available over-the-counter in oil and capsule form, usually in combination with one another as opposed to each on their own.

And its this combination that researchers say is the problem.

"The advice to take omega-3s for the good of your heart is pervasive, but previous studies have shown that science doesn't really back this up for every single omega-3," says Viet T. Le, the principal study researcher and a cardiovascular physician assistant at the Intermountain Heart Institute. "Our findings show that not all omega-3s are alike and that EPA and DHA combined together, as they often are in supplements, may void the benefits that patients and their doctors hope to achieve."

For the study, which was presented at the virtual 2021 conference of the American College of Cardiology, researchers combed the Intermountain database, called INSPIRE, which is home to more than 35,000 blood samples from more than 25,000 patients dating back to 1993.

In the database, researchers found 987 patients who had undergone coronary angiographic studies. An angiogram is a type of X-ray that uses dye inserted into the coronary arteries to give physicians a visual overview of how well blood is flowing through those vessels and allows for the identification of blockages and buildup along arterial walls.

These nearly 1,000 patients had undergone their first angiographic study at Intermountain Healthcare between 1994 and 2012. From those blood samples, the circulating levels of EPA and DHA in their blood were measured.

Researchers then tracked those patients for 10 years, looking for major cardiac problems, including heart attack, stroke, heart failure requiring hospitalization, or death.

Unsurprisingly, patients with the highest levels of EPA in their blood experienced fewer major cardiac events, but when researchers compared levels of EPA with levels of DHA, the story changed a little.

They discovered that patients with higher levels of DHA showed fewer positive effects of EPA, and patients whose circulating DHA was higher than EPA were at greater risk than the other groups examined.

These findings contradict the commonly held view that all omega-3s are heart-healthy and that combination supplements are the best way to capitalize on their purported benefits.

Based on these and other findings, we can still tell our patients to eat omega-3 rich foods, but we should not be recommending them in pill form as supplements or even as combined (EPA plus DHA) prescription products," Le says. "Our data adds further strength to the findings of the recent REDUCE-IT (2018) study, that EPA-only prescription products reduce heart disease events."

While omega-3 combination supplements are now being called into question, there are several other proven ways to improve heart health. The American Heart Association providesseven simple ways to boost your heart health and decrease your risk of heart trouble down the line.

Exercise.Your heart is a muscle, and like any other muscle in your body, it needs a good workout to stay fit. Walking even 10 minutes a day can improve your heart health and lessen your risk of major cardiac events.

Eat a heart-healthy diet. Limit portion sizes and eat plenty of fruits and veggies, whole grains (such as whole-grain bread, steel-cut oatmeal, and high fiber cereals) and lean proteins like chicken and fish. Also use healthy fats, like olive or avocado oil, and trim fat from red meat before cooking.

If you smoke, quit. Smoking causes myriad well-documented health problems, including increasing your risk of developing atherosclerosis, the deposit of fatty buildup on arterial walls.

Keep your blood pressure in check. Elevated blood pressure can cause your arteries to lose the elasticity thats vital to the efficient movement of blood throughout the body. This loss of elasticity can result in decreased blood flow to your heart itself and increase your risk of heart disease.

Maintain a healthy weight. Carrying extra weight means your heart needs to work harder to pump blood, which puts you at increased risk of developing high blood pressure.

Watch your cholesterol. Limit your intake of foods that are high in saturated fat andtrans fat, and have your blood cholesterol measured on a regular basis.

Maintain healthy blood sugar levels. Long-term high blood sugar can damage the blood vessels and nerves that supply the heart, making your risk of developing heart problems or experiencing a major cardiac event higher. To reduce blood sugar levels, limit sugary foods and beverages, stay active, and maintain a healthy weight.

See the article here:
Mix of Omega-3s in Supplements May Blunt Heart Benefits - Everyday Health

Read More..

Interdisciplinary Department of Medicine, University of Bari Aldo Moro Medical School, Bari, 70124, Italy

Correspondence: Giuseppina PiazzollaInterdisciplinary Department of Medicine, University of Bari Aldo Moro Medical School, Policlinico, Piazza G. Cesare 11, Bari, 70124, ItalyFax +39 080 5478126Email [emailprotected]

Introduction: New antidiabetic drugs have simplified treatment regimens in patients with type-2 diabetes (T2D). More importantly, they have proven to reduce cardiovascular risk by lowering insulin-resistance, blood pressure and body weight, in addition to avoiding inappropriate insulin therapy, responsible for hypoglycemic episodes and weight gain. In this context, accurate assessment of the metabolic status of T2D patients becomes essential. The C-peptide assay is a simple but often overlooked test that can provide a fundamental contribution to the correct disease classification and optimal therapeutic management of diabetic patients.Clinical Case: We report the case of a 72-year-old patient, treated with insulin for 26 years after a diagnosis of type-1 diabetes (T1D), resulting in inadequate glycemia control and a severe evolution of cardiovascular complications. After an accurate evaluation of the clinical history, phenotype and laboratory data, including the determination of C-peptide serum levels, a diagnosis was made of T2D not T1D. Considering the patients very high cardiovascular risk and dysmetabolic profile, insulin therapy was discontinued and more appropriate therapy with dulaglutide and metformin was instituted. These overall therapeutic modifications yielded remarkable clinical advantages in terms of the glycometabolic profile, weight reduction, abdominal circumference and body mass index decrease, as well as a better quality of life, with complete resolution of the dangerous hypoglycemic episodes.Conclusion: In the era of new cardioprotective antidiabetic drugs, we believe the importance of the C-peptide assay should be re-evaluated in order to avoid misdiagnosis and to improve the therapeutic approach to T2D.

Keywords: diabetes, metabolic syndrome, hypoglycemia, obesity, dulaglutide, quality of life

Type-2 diabetes (T2D) is becoming more prevalent in the general population, especially in individuals over the age of 65 years, and is closely linked to cardiovascular diseases (CVDs). The treatment of diabetes is challenging, since the aims addressed are to achieve metabolic compensation and to reduce micro and macrovascular complications.1,2 Cardiovascular outcome trials (CVOTs) have provided useful information on the cardiovascular safety and cardio- and nephro-protection achieved with the new anti-diabetes drugs, namely Glucagon-like-peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose transporter-2 inhibitors (SGLT2i). These are both very effective pharmacological approaches, currently recommended for T2D, particularly in patients with established heart disease or at high risk for cardiovascular events. Nowadays, since the emergence of these revolutionary drugs for the treatment of T2D, routine determination of the pancreatic cells reserve has become essential. C-peptide is a biomarker of residual -cell function and can provide valuable clinical information, but it is rarely used to classify the diabetes type in clinical practice or to manage T2D.3,4 While type-1 diabetes (T1D) is an autoimmune process leading to the loss of pancreatic -cell function, T2D is a heterogeneous disease characterized by a combination of varying degrees of relative insulin secretory deficiency and insulin-resistance linked to the metabolic syndrome, featuring a slower, more protracted course. We report the case of a 72-year-old dysmetabolic patient, treated with insulin for 26 years after a diagnosis of T1D, who developed severe CVDs. An accurate evaluation of the clinical history, phenotype and especially the measurement of C-peptide levels allowed us to correct the T1D misdiagnosis to T2D, and set up a more appropriate therapy resulting in metabolic and glycemic advantages and a marked improvement of the patients quality of life. Regular use of the C-peptide assay in clinical practice, particularly at the time of first diagnosis, might help clinicians to avoid inappropriate use of insulin and prevent a detrimental delay in the introduction of new cardioprotective antidiabetic drugs.

A 72-year-old man with a history of T1D was admitted to the Department of Internal Medicine complaining of alternating hyperglycemia and numerous hypoglycemic episodes.

The patient signed the informed consent for the acquisition, analysis, and publishing of the anonymized data collected. Since no personal identification data were used in this manuscript, the ethics committee approval is not needed.

The patient had been diagnosed with T1D in 1994 at a diabetes center and treated with insulin thereafter, continuing follow-up at an endocrinology department. He was a former smoker (15 pack-years), non-drinker, and reported a family history of diabetes and cardiovascular diseases. After the T1D diagnosis, his clinical course was complicated by peripheral neuropathy, arterial hypertension, OSAS (obstructive sleep apnea syndrome) and multiple episodes of angina, requiring placement of intracoronary stents for an N-STEMI (non-ST-segment elevation myocardial infarction) in 2011. At the time of our first observation, the patients medications included a -blocker, an angiotensin-converting enzyme (ACE)-inhibitor, double antiplatelet therapy, ranolazine, statins, furosemide and pregabalin. Diabetes medications consisted of basal-bolus insulin therapy, in the form of long-acting insulin glargine 30 I.U. at bedtime, and short-acting insulin lispro at meals (8 I.U. at breakfast and dinner, 15 I.U. at lunch). Last year, his family doctor had recommended increasing the doses of short-acting insulin at meals, in order to improve the glycemic control, but his conditions were deteriorating due to the onset of numerous hypoglycemic episodes (up to 4 per day) and an increased appetite. At physical examination, the patient had a high body mass index (BMI) and abdominal circumference, and his condition was classified as metabolic syndrome with class I obesity (Table 1). The laboratory tests showed unsatisfactory glycemic compensation and a suboptimal lipid profile but preserved renal function (see Table 1). Serum C-peptide levels had never been determined in any of the patients clinical records. Nor had the presence of autoantibodies to diabetes-associated antigens ever been evaluated since the T1D diagnosis. The fasting serum C-peptide assay was performed and resulted within the normal range. The patients clinical history, as well as his phenotype, suggested a diagnosis of T2D rather than T1D. This view was confirmed by the finding of normal C-peptide levels. Ezetimibe and metformin were added to the therapy, and the short-acting insulin dose was tapered until complete discontinuation at 10 days. Owing to the patients very high cardiovascular risk, either an SGLT2i or a GLP-1RA was particularly indicated.58 His obesity status and referred increase in appetite led us to institute therapy with dulaglutide, a long-acting GLP-1RA. Over the next 4 weeks, the long-acting insulin doses were also completely discontinued. After 4 weeks of treatment, the patients glycated hemoglobin values had normalized and no further hypoglycemic episodes occurred. After 2 months of dulaglutide treatment, and the insulin discontinuation, the patient achieved 10 kg of weight loss and a reduction in abdominal circumference by 13 cm.

Table 1 Relevant Patient Data Before (Baseline) and 2, 4 and 8 Weeks After Instituting the New Therapy

In past decades, randomized trials compared the effect of more versus less intensive glycemic control, showing that the potential benefit of strict glycemic control on microvascular diabetes complications was counteracted by the increased risk of cardiovascular disease and mortality.9 In contrast to the more traditional focus on glycemic control, new diabetes guidelines increasingly highlight the importance of multifactorial management focused on cardiovascular risk benefits. Recent CVOTs have provided useful information on cardio- and nephro-protection conferred by the new antidiabetic drugs.6,10 In this context, an accurate evaluation of the diabetic disease and correct determination of pancreatic reserves are crucial to ensure optimal care. C-peptide is the part of pro-insulin cleaved prior to co-secretion with insulin by pancreatic -cells. It is produced in equimolar amounts to endogenous insulin and provides the best gauge of -cells ability to produce insulin in diabetic patients, including those treated with exogenous insulin.3,11,12 The determination of serum C-peptide levels can help to identify subjects whose residual -cell function is still sufficient to indicate the use of emerging antidiabetic drugs, avoiding the administration of exogenous insulin. Instead, very low C-peptide levels, suggestive of a defective -cell secretory function, have been indicated as predictors of poor response to GLP-1 RA.13 Serious errors may arise when T1D is diagnosed later in life; in fact, more than 50% of the patients diagnosed with T1D after age 35 have been found to have T2D at long-term follow-up.14 Furthermore, among T2D patients, too often the timing of insulin administration is anticipated due to suboptimal glycemic control, potentially leading to hypoglycemic episodes, weight gain and increased cardiovascular risk. In this context, the C-peptide assay is a simple, inexpensive but often overlooked laboratory test that can provide an essential contribution to the differential diagnosis between T1D and T2D and to a correct determination of pancreatic reserves in T2D.15,16 This patient did not have the typical hallmarks of immune-mediated T1D and his normal C-peptide value was poorly compatible with a diagnosis of T1D 26 years after the disease onset. The patients complaint of an increased appetite, the absence of clinical evidence of heart failure, as well as our aim to simplify the therapeutic schedule, constituted the rationale for prescribing metformin and dulaglutide and discontinuing exogenous insulin therapy. After only 4 weeks of treatment the C-peptide levels had further increased, indicating a satisfactory residual -cell function. Following these therapeutic changes, the patients quality of life significantly improved, thanks to the reduced subcutaneous administration of drugs (from 4 per day to 1 per week) and resolution of the frequent hypoglycemic episodes. Hypoglycemia has long been recognized as a dangerous side effect of treating diabetes with insulin or insulin secretagogues. Indeed, hypoglycemia is associated with negative life consequences, ranging from the disruption of daily activities to psychosocial problems for both patients and their family members, in addition to increasing cardiovascular risk and mortality.9,17 After a few days of treatment with dulaglutide and insulin discontinuation, the quality of life of our patient had improved considerably, as also his therapeutic compliance. Other clinical advantages included the normalization of glycated hemoglobin values, a decreased appetite, 10 kg of weight loss in only 2 months and a 13 cm reduction in abdominal circumference, all yielding unquestionable health benefits.

The study's strong point lies in the evidence that C-peptide evaluation changed the diagnosis and therapeutic management of our patient. Accordingly, the use of C-peptide as a preliminary test in clinical practice may help clinicians to institute the most suitable antidiabetic therapy as early as possible, and also encourage them to refrain from prescribing insulin at all, when it may actually be useless.

The main limitation is that the c-peptide assay is a well-known but overlooked test and the official guidelines on medical care in diabetes and pre-diabetes do not exploit it for the correct classification of patients. For this reason, there are not yet data in the literature to support our view that re-evaluating c-peptide dosage as a key tool may offer a novel approach to diabetic disease management.

We believe that in the era of the new cardioprotective antidiabetic drugs, the C-peptide assay may be the natural laboratory complement to clinical signs and symptoms in T2D patients, offering the advantage of avoiding inappropriate prescription of insulin to dysmetabolic and insulin-resistant patients. A correct clinical classification of our patient and the determination of a preserved pancreatic -cell function with this simple test led us to introduce a more beneficial and appropriate antidiabetic therapy. The application of this test in clinical practice might have important implications on cardioprotection and body wellness in diabetic patients. Certainly, inappropriate or overuse of insulin in dysmetabolic and high cardiovascular risk patients is no longer acceptable, and should be considered deleterious to their health and quality of life. This strongly suggests that the C-peptide assay needs to be re-evaluated as a key tool for use in daily clinical practice.

T2D, type-2 diabetes; T1D, type-1 diabetes; CVD, cardiovascular disease; CVOTs, cardiovascular outcome trials; GLP-1RA, glucagon-like-peptide-1 receptor agonists; SGLT2i, sodium-glucose transporter-2 inhibitors; OSAS, obstructive sleep apnea syndrome; N-STEMI, non-ST-segment elevation myocardial infarction; ACE, angiotensin-converting enzyme; I.U., International Units; BMI, body mass index; HbA1c, glycated hemoglobin; LDL, low-density lipoprotein; HDL, high-density lipoprotein; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; DBP, diastolic blood pressure.

We are grateful to Mary Pragnell for language revision.

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

The authors report no actual or potential conflicts of interest in relation to this work.

1. Beckman JA, Paneni F, Cosentino F, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J. 2013;34:24442452. doi:10.1093/eurheartj/eht142

2. Low Wang CC, Hess C, Hiatt WR, et al. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations. Circulation. 2016;133:24592502. doi:10.1161/CIRCULATIONAHA.116.022194

3. Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med. 2013;30:803817. doi:10.1111/dme.12159

4. Hope SV, Wienand-Barnett S, Shepherd M. Practical Classification Guidelines for Diabetes in patients treated with insulin: a cross-sectional study of the accuracy of diabetes diagnosis. Br J Gen Pract. 2016;66:E315E322. doi:10.3399/bjgp16X684961

5. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized placebo-controlled trial. Lancet. 2019;394:121130.

6. Giorgino F, Caruso I, Moelimann J, et al. Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure. Metabolism. 2020;104:154045. doi:10.1016/j.metabol.2019.154045

7. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular disease developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255323.

8. Standards of medical care in diabetes 2021 ADA (American Diabetes Association). Diabetes Care. 2021;44(Suppl1):S111S124. doi:10.2337/dc21-S009

9. Gerstein HC, Miller ME, Byington RP, et al. Effect of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):25452559.

10. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:3139. doi:10.1016/S0140-6736(18)32590-X

11. Becht FS, Walther K, Martin E, et al. Fasting C-peptide and related parameters characterizing insulin secretory capacity for correctly classifying diabetes type and for predicting insulin requirement in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2016;124:148156. doi:10.1055/s-0035-1565177

12. Ludvigsson J. C-peptide in diabetes diagnosis and therapy. Front Biosci. 2013;5:214223. doi:10.2741/E609

13. Jones AG, McDonald TJ, Shields BM, et al. Markers of -cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes. Diabetes Care. 2016;39:250.

14. Thomas NJ, Jones SE, Weedon MN, et al. Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. Lancet Diabetes Endocrinol. 2018;6:122129. doi:10.1016/S2213-8587(17)30362-5

15. Munshi MN, Hayes M, Sternthal A, et al. Use of serum C-peptide level to simplify diabetes treatment regimens in older adults. Am J Med. 2009;122:395397. doi:10.1016/j.amjmed.2008.12.008

16. Nathan D. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37:916. doi:10.2337/dc13-2112

17. Rossi MC, Nicolucci A, Ozzello A, et al. Impact of severe and symptomatic hypoglycemia on quality of life and fear of hypoglycemia in type 1 and type 2 diabetes. Results of the Hypos-1 observational study. Nutr Metab Cardiovasc Dis. 2019;29(7):736743. doi:10.1016/j.numecd.2019.04.009

18. Pagana KD, Pagana TJ, Pagana TN. Mosbys Diagnostic & Laboratory Test Reference. 14th ed. St. Louis Mo: Elsevier; 2019.

19. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidemia: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111188.

Link:
When Inappropriate Use of Insulin is Dangerous: The Utility of C-Pepti | DMSO - Dove Medical Press

Read More..

Contact Us Today

Page 402«..1020..401402403404..410420..»

Home » Page 402